Drugs / TAK-951
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06768658 | Mar 2022 → Jan 2023 | — | Takeda | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06610279 | Jan 2022 → Sep 2023 | — | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT04486950 | Jul 2020 → May 2021 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT05567393 | Mar 2019 → Nov 2020 | — | Takeda | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04557189 | Oct 2020 → Mar 2022 | — | Takeda | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-951 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06610279 ↗ |
| Route | Intravenous | “TAK-951 intravenous infusion.” NCT04486950 ↗ |